Author

T. D. Scobey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 6 Organism:mouse· 6 Organism:non-human primate· 2 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

R. S. Baric· 6 shared D. R. Martinez· 3 shared E. Lee· 3 shared K. Mansouri· 3 shared L. V. Tse· 3 shared M. Barr· 3 shared R. J. Edwards· 3 shared R. Parks· 3 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

R. S. Baric

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice

D. Martinez, A. R. Schaefer, T. Gavitt, M. Mallory, E. Lee, N. Catanzaro, H. Chen, K. Gully, T. D. Scobey, P. Korategere, A. Brown, L. Smith, R. Parks, M. Barr, A. Newman, , K. O. Saunders

This study develops a trivalent RBD nanoparticle vaccine that protects mice against both merbecovirus and sarbecovirus challenges, including SARS-CoV, MERS-CoV, and SARS-CoV-2.

Cell Reports · Oct 1, 2023Peer-reviewedImmunology

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

D. R. Martinez, F. Moreira, M. R. Zweigart, K. L. Gully, G. De la Cruz, A. Brown, L. E. Adams, N. Catanzaro, B. Yount, T. J. Baric, M. Mallory, H. Conrad, S. R. May, S. Dong, T. D. Scobey, , T. P. Sheahan

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

bioRxiv · Jun 27, 2023 · PreprintMicrobiology

A Multitrait Locus Regulates Sarbecovirus Pathogenesis

R. S. Baric, A. Schaefer, S. R. Leist, L. Gralinski, D. Martinez, E. S. Winkler, K. Okuda, P. E. Hawkins, K. L. Gully, R. L. Graham, T. D. Scobey, T. A. Bell, P. Hock, G. D. Shaw, J. F. Loome, , M. T. Ferris

The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.

bioRxiv · Jun 1, 2022Microbiology

SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

K. O. Saunders, E. Lee, R. Parks, D. R. Martinez, D. Li, H. Chen, R. J. Edwards, S. M. C. Gobeil, M. Barr, K. Mansouri, S. M. Alam, L. L. Sutherland, F. Cai, A. Sanzone, M. Berry, , B. F. Haynes

This study shows that SARS-CoV-2 vaccines induce neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, and batCoVs in monkeys.

bioRxiv · Feb 17, 2021 · PreprintImmunology

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

D. Li, R. J. Edwards, K. Manne, D. R. Martinez, A. Schafer, S. M. Alam, K. Wiehe, X. Lu, R. Parks, L. L. Sutherland, T. H. Oguin, C. McDanal, L. G. Perez, K. Mansouri, S. M. C. Gobeil, , Petzol

This study examines SARS-CoV-2 neutralizing and infection-enhancing antibodies, showing in vitro enhancement does not always lead to in vivo disease enhancement, but can cause increased lung inflammation in monkeys.

bioRxiv · Dec 31, 2020 · PreprintImmunology

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19

C. G. Rappazzo, L. V. Tse, C. I. Kaku, D. Wrapp, M. Sakharkar, D. Huang, L. M. Deveau, T. J. Yockachonis, A. S. Herbert, M. B. Battles, C. M. O'Brien, M. E. Brown, J. C. Geoghegan, J. Belk, L. Peng, , L. M. Walker

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

bioRxiv · Nov 17, 2020 · PreprintImmunology

Trypsin treatment unlocks barrier for zoonotic coronaviruses infection

V. D. Menachery, K. Dinnon, B. Yount, E. T. McAnarney, L. Gralinski, A. E. Hale, R. Graham, T. D. Scobey, S. J. Anthony, L. Wang, B. S. Graham, S. H. Randell, W. I. Lipkin, R. S. Baric

This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.

bioRxiv · Sep 16, 2019Microbiology